{"id":959780,"date":"2026-05-07T08:34:38","date_gmt":"2026-05-07T12:34:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/"},"modified":"2026-05-07T08:34:38","modified_gmt":"2026-05-07T12:34:38","slug":"dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/","title":{"rendered":"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, May  07, 2026  (GLOBE NEWSWIRE) &#8212; Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (\u201cDogwood\u201d or the \u201cCompany\u201d), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets.<\/p>\n<p>\n        <strong>About Dogwood Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron<sup>\u00ae<\/sup>\u00a0and SP16 IV.<\/p>\n<p align=\"justify\">Our lead product candidate, Halneuron<sup>\u00ae<\/sup>,\u00a0is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron<sup>\u00ae<\/sup>\u00a0has been granted fast track designation from the FDA for the treatment of CINP. Halneuron<sup>\u00ae<\/sup>\u00a0is a non-opioid, Na<sub>V<\/sub>\u00a01.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron<sup>\u00ae<\/sup>\u00a0treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (\u201cCINP\u201d). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b chemotherapy-induced pain and peripheral neuropathy trial is fully funded by the National Cancer Institute.<\/p>\n<p align=\"justify\">Dogwood Therapeutic\u2019s largest shareholder is a member of CK Life Sciences Int\u2019l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e4oNN5MZP50HNtx4ekfc9CUbSsfZlNsZ3kzd_XBFNAegE1ATj92MesRbPoNeSB_eDDwacRhRdlklv12KaTFj4zN03W7d8azQkb2tDQ9tbV-VYiUybZNsxYSMZJB7qT4MC64z0d3N9Pqsvqr_sDJIWoaDPpNGG8SZYMPdOCWatO0X5HRbFY4KMqJHs-XNAW4JIkf9JjlSl73JALOO_xEEy5m77nLFmFGmR62OjCpiCo2nsBt4N_2R1Bxs5FqiI2TArpAQEMF8vetJFkXuEhBPqrCr6i4upADJzQSQZVqhHqYs7lQwm-gwINImLwGUbmHsZ2gTkiQAHvGcbSb9CVk9e9-rl6w8KZaim42CLaP0A1aYEKaAvRFbrqlp9w6s4m5nBmhNCIbcZOjg09rzoBUMt7ZIdv177OKEOuSb_QtNbzA=\" rel=\"nofollow\" target=\"_blank\">www.dwtx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d &#8220;will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood\u2019s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/>daniel@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTY5MTA1MTItNjI4OC00OWMyLTkyZTctMDM3ZTNiZmZjZmUxLTEyMTU1NDctMjAyNi0wNS0wNy1lbg==\/tiny\/Dogwood-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) &#8212; Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (\u201cDogwood\u201d or the \u201cCompany\u201d), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron\u00ae\u00a0and SP16 IV. Our lead product candidate, Halneuron\u00ae,\u00a0is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron\u00ae\u00a0has been granted fast track designation from the FDA for the treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959780","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) &#8212; Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (\u201cDogwood\u201d or the \u201cCompany\u201d), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron\u00ae\u00a0and SP16 IV. Our lead product candidate, Halneuron\u00ae,\u00a0is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron\u00ae\u00a0has been granted fast track designation from the FDA for the treatment &hellip; Continue reading &quot;Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T12:34:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026\",\"datePublished\":\"2026-05-07T12:34:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/\"},\"wordCount\":557,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/\",\"name\":\"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=\",\"datePublished\":\"2026-05-07T12:34:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/","og_locale":"en_US","og_type":"article","og_title":"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Market Newsdesk","og_description":"ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) &#8212; Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (\u201cDogwood\u201d or the \u201cCompany\u201d), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron\u00ae\u00a0and SP16 IV. Our lead product candidate, Halneuron\u00ae,\u00a0is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron\u00ae\u00a0has been granted fast track designation from the FDA for the treatment &hellip; Continue reading \"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-07T12:34:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026","datePublished":"2026-05-07T12:34:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/"},"wordCount":557,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/","name":"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=","datePublished":"2026-05-07T12:34:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNDk4OCM3NTg4ODYxIzIyMDM5OTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959780"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959780\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}